Skip to content
Biodatica
Start free

BioNTech SE

Louisville, Kentucky

OncologyantibodyPhase IIListed · BNTX

This company trades under its own ticker, so it sits outside Biodatica’s pre-ticker window. The record stays here because its filings are real, but the feed leaves listed companies out unless you ask for them.

Compare Sign in to watch

What changed

Phase II trial registered: A Clinical Trial to Test if the Investigational Drug BNT329 is Safe and Potentially Beneficial for People With Advanced Solid Tumors Known to Express the Tumor Marker CA19-9

2d agoTrial registeredJul 17, 2026Source filing (opens the source filing in a new tab)

Momentum

96no change

Momentum 96 out of 100, unchanged since the last recompute.

Accelerating: several high-weight events landed recently.

Runway (estimate)

—unknown

No disclosed raise on file, so there is nothing to model from.

Stage

Phase II

The furthest-along thing in the public record. Not a projection.

Runway is an estimate: the last disclosed raise (SEC Form D) minus a modeled burn rate for the company’s stage and therapeutic area. It is not a disclosure, and companies routinely raise non-dilutive money we can’t see. How this is calculated.

Grant to raise

Every record Biodatica has resolved onto this company, newest first, each linked to the filing it came from. Where a source publishes no stable deep link for a record, the identifier is shown so you can look it up yourself.

  1. Trial

    PHASE1 registered

    Feb 9, 2026

    HIV -1 Infection · RECRUITING · sponsor: BioNTech SE · A Clinical Trial Investigating the Safety and Biological Activity of the Antibody BNT351 in Adults Living Without and With HIV

    ClinicalTrials.gov · NCT07392372 (opens the source filing in a new tab)

  2. Trial

    PHASE1/PHASE2 registered

    Nov 18, 2025

    Advanced Solid Cancers · RECRUITING · sponsor: BioNTech SE · A Clinical Trial to Test if the Investigational Drug BNT329 is Safe and Potentially Beneficial for People With Advanced Solid Tumors Known to Express the Tumor Marker CA19-9

    ClinicalTrials.gov · NCT07186842 (opens the source filing in a new tab)

  3. Trial

    PHASE1 registered

    Jan 13, 2025

    Advanced Solid Tumor · RECRUITING · sponsor: BioNTech SE · Safety and Preliminary Effectiveness of BNT317, an Investigational Therapy for Advanced Solid Tumors

    ClinicalTrials.gov · NCT06750185 (opens the source filing in a new tab)

  4. Trial

    PHASE1/PHASE2 registered

    Mar 22, 2022

    Solid Tumor · TERMINATED · sponsor: BioNTech SE · Safety and Preliminary Efficacy Trial of BNT142 in Patients With CLDN6-positive Solid Tumors

    ClinicalTrials.gov · NCT05262530 (opens the source filing in a new tab)

  5. Trial

    PHASE1 registered

    Mar 1, 2015

    Melanoma · COMPLETED · sponsor: BioNTech SE · Evaluation of the Safety and Tolerability of i.v. Administration of a Cancer Vaccine in Patients With Advanced Melanoma

    ClinicalTrials.gov · NCT02410733 (opens the source filing in a new tab)

Biodatica publishes impersonal research shown identically to every subscriber. This dossier is informational only, it is not investment advice, and the momentum and runway figures are estimates derived from public filings. The underlying records are U.S. government works. Disclosures · Data sources